BNP Paribas Financial Markets Grows Stock Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)

BNP Paribas Financial Markets raised its position in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 2,002.5% during the third quarter, Holdings Channel reports. The fund owned 67,702 shares of the biopharmaceutical company’s stock after acquiring an additional 64,482 shares during the period. BNP Paribas Financial Markets’ holdings in Puma Biotechnology were worth $173,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PBYI. Rice Hall James & Associates LLC raised its position in shares of Puma Biotechnology by 3.3% during the 2nd quarter. Rice Hall James & Associates LLC now owns 144,792 shares of the biopharmaceutical company’s stock valued at $472,000 after purchasing an additional 4,686 shares during the period. Patriot Financial Group Insurance Agency LLC raised its stake in Puma Biotechnology by 72.7% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 8,000 shares during the period. Royce & Associates LP boosted its stake in Puma Biotechnology by 71.8% in the 3rd quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 8,427 shares during the period. Squarepoint Ops LLC grew its holdings in Puma Biotechnology by 17.7% during the 2nd quarter. Squarepoint Ops LLC now owns 71,391 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 10,757 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Puma Biotechnology during the third quarter valued at approximately $34,000. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Analyst Upgrades and Downgrades

PBYI has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, November 20th. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th.

Puma Biotechnology Stock Performance

Shares of PBYI opened at $2.92 on Wednesday. The stock has a 50-day moving average of $2.94 and a two-hundred day moving average of $3.02. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. The stock has a market cap of $143.34 million, a P/E ratio of 6.08 and a beta of 1.08. Puma Biotechnology, Inc. has a one year low of $2.22 and a one year high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The firm had revenue of $80.50 million for the quarter, compared to analyst estimates of $71.32 million. During the same quarter last year, the firm posted $0.12 EPS. As a group, research analysts predict that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.